AC
EIGR

Ascend Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ascend Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-289
Closed -$2.46M – 202
2015
Q1 		$2.46M Buy
+289
New +$2.53M 0.08% 133

Other funds holding EIGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Ascend Capital's EIGR Position: Q2 2015 in Review

Ascend Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2015, closing a stake of 289 shares — an estimated $2.46M sold.

Ascend Capital first reported a position in EIGR in Q1 2015 and held it in 1 quarter. The position peaked at $2.46M in Q1 2015. 44 funds tracked by Wall St. Rank hold EIGR as of Q2 2015.

  • Ascend Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Ascend Capital sold 289 Eiger BioPharmaceuticals, Inc. shares in Q2 2015, an estimated $2.46M.
  • Ascend Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Ascend Capital's Eiger BioPharmaceuticals, Inc. position peaked at $2.46M in Q1 2015.
  • 44 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2015.

Based on Ascend Capital's 13F filing for Q2 2015, filed 13 Aug 2015.